Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Reorganizes R&D Work Into 13 Competitive Units

This article was originally published in PharmAsia News

Executive Summary

Eisai plans to reorganize its research and development operations to make the unit more competitive with the work of other drug makers. Under the plan, MGI Pharma researchers, acquired by Eisai when it bought the firm last year, are to become part of an oncology group, one of 13 units within the R&D division. Each group is to consist of about 100-200 staff ready to operate under the new arrangement in July. The plan includes incentives to the units to compete against each other and other drug makers and each unit is to carry through development from beginning to end. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts